Related Experiment Videos
mb-1: a new marker for B-lineage lymphoblastic leukemia
V Buccheri1, B Mihaljević, E Matutes
1Academic Department of Haematology and Cytogenetics, Royal Marsden Hospital, London, UK.
Blood
|August 1, 1993
Summary
The mb-1 antibody is a sensitive and specific marker for identifying B-lineage acute lymphoblastic leukemia (ALL) and biphenotypic leukemia. It aids in classifying B-cell precursor ALL and detecting myeloid leukemias with B-cell features.
Area of Science:
- Immunology
- Hematology
- Oncology
Background:
- Accurate classification of acute leukemia subtypes is crucial for effective treatment.
- Identifying B-lineage and biphenotypic leukemias requires specific and sensitive diagnostic markers.
Purpose of the Study:
- To evaluate the specificity and reactivity of the mb-1 antibody in various acute leukemia subtypes.
- To determine the utility of mb-1 in identifying B-cell precursor acute lymphoblastic leukemia (ALL) and biphenotypic leukemia.
Main Methods:
- Immunocytochemistry using a specific monoclonal antibody against the Ig-linked mb-1 polypeptide.
- Analysis of 165 acute leukemia cases (88 ALL, 77 AML).
- Assessment of mb-1 expression in relation to B-cell and myeloid antigen coexpression and Ig heavy chain gene rearrangement.
Main Results:
- Mb-1 was expressed in 89% of B-cell precursor ALL cases, including early-B-ALL, pre-B-ALL, and common-ALL.
- All T-lineage ALL and 93.5% of AML cases were mb-1 negative.
- Four AML cases expressing mb-1 were biphenotypic, showing other B-cell antigens and Ig heavy chain gene rearrangement.
- Mb-1 demonstrated high correlation with Ig heavy chain gene rearrangement in biphenotypic AML.
Conclusions:
- Mb-1 is a sensitive and specific reagent for B-lineage blasts.
- Mb-1 aids in the classification of B-cell precursor ALL.
- Mb-1 is valuable for identifying biphenotypic leukemia presenting as AML.